<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="222575">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185614</url>
  </required_header>
  <id_info>
    <org_study_id>BMT109</org_study_id>
    <secondary_id>75190</secondary_id>
    <secondary_id>BMT109</secondary_id>
    <nct_id>NCT00185614</nct_id>
  </id_info>
  <brief_title>Mixed Chimera Allo Transplantation in Multiple Myeloma</brief_title>
  <official_title>Mixed Chimera Allogeneic Transplantation With or Without Allogeneic Idiotyped Pulsed Dendritic Cells for the Treatment of Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine toxicity and feasibility of mixed chimera allogeneic hematopoietic cell
      transplants for multiple myeloma; prepare and vaccinate patients with allogenic dendritic
      cell vaccinations following mixed chimera allogeneic hematopoietic cell transplants
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival, event-free survival and relapse rate with an intent-to-treat analysis. Results will be compared to allogeneic HCT reported results.</measure>
    <time_frame>July 2011</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Development of Graft Versus Host Disease (GVHD) in vaccinated patients</measure>
    <time_frame>July 2011</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of GVHD in concurrent myeloma patients receiving allogeneic HCT at our institution who are not candidates for vaccination.</measure>
    <time_frame>July 2011</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Blood Cancer</condition>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous then nonmyeloablative allogeneic transplant</intervention_name>
    <description>stem cell transplantation</description>
    <other_name>BMT</other_name>
    <other_name>Blood and Marrow Transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>4 gm/m2, IV</description>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>cytophosphane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>200 mg/m2; iv</description>
    <other_name>Alkeran</other_name>
    <other_name>Melphalan hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporin</intervention_name>
    <description>5 mg/kg; iv or po</description>
    <other_name>cyclosporine</other_name>
    <other_name>cyclosporin A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>15 mg/kg</description>
    <other_name>MMF</other_name>
    <other_name>CellCept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Multiple myeloma. Eligible patients may have early or relapsed disease. Patients must
             have Stage II-III disease or have progression after initial treatment of Stage I
             disease.

          -  Age less than or equal to 70 years.

          -  No prior therapy which would preclude the use of low-dose total body irradiation.

          -  Patients must have their pathology reviewed and the diagnosis confirmed at Stanford
             University Medical Center. Patients with smoldering multiple myeloma, monoclonal
             gammopathy of unknown significance, or primary amyloidosis will be excluded from this
             study.

          -  Patients must have a Karnofsky performance status greater than 70%.

          -  DLCO &gt;=60% predicted.

          -  ALT and AST must be &lt; 2X normal. Total bilirubin less than 2 mg/dl.

          -  Serum creatinine &lt; 2.0 or 24-hour creatinine clearance &gt;=60 ml/min.

          -  Patients must be HIV negative.

          -  Pregnant or lactating women will not be eligible to participate.

          -  Patients must provide signed, informed consent.

          -  Patients must have an HLA-identical sibling donor.

        Exclusion Criteria:

          -  Severe psychological or medical illness

          -  Patients who have undergone prior allogeneic hematopoietic cell transplantation will
             not be eligible for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen-Kai Weng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <lastchanged_date>April 18, 2011</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <responsible_party>
    <name_title>Wen-Kai Weng, Principal Investigator</name_title>
    <organization>Stanford University School of Medicine</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
